Therapy News and Research

RSS

Eli Lilly, Alnara sign definitive merger agreement

Eli Lilly and Company and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metabolic diseases. Alnara's lead product in development is liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT).

2 Jul 2010

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Bristol-Myers Squibb Company and AstraZeneca today announced results up to 76-weeks from a Phase 3 study of ONGLYZA(TM) (saxagliptin) as initial combination therapy with metformin, which produced long-term glycemic improvement (as measured by glycosylated hemoglobin level (HbA1c)) in treatment-naive adults with type 2 diabetes mellitus inadequately controlled on diet and exercise compared to treatment with an investigational 10 mg dose of saxagliptin or metformin alone.

2 Jul 2010

Modified Citrus Pectin holds promise against prostate cancer

Researchers at Columbia University recently analyzed the positive effects of Modified Citrus Pectin (MCP) on human and mouse prostate cancer cell lines. The results, as reported by lead researcher Dr. Aaron Katz in the most recent publication of Integrative Cancer Therapies, show that MCP inhibits cell proliferation and induces apoptosis (programmed cell death) in both androgen-dependent and androgen-independent cancer cells in a time and dose-dependent manner.

2 Jul 2010

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire plc, the global specialty biopharmaceutical company, today announced positive data from its long-term extension to its open label Phase I/II study (TKT-025 EXT) for VPRIV® (velaglucerase alfa), the company's enzyme replacement therapy for patients with type 1 Gaucher disease. The data were presented at the 9th Annual European Working Group on Gaucher Disease (EWGGD) in Cologne, Germany, and add to the growing body of clinical evidence which supports the safety and sustained efficacy of VPRIV.

2 Jul 2010

EU requirement for HIV, hepatitis screening of ART couples at each donation unnecessary, distressing

European legislation that requires all couples undergoing assisted reproduction treatment (ART) to be screened for HIV and hepatitis at the time of every sperm or egg donation is unnecessary, expensive, and potentially distressing for patients, the 26th annual meeting of the European Society of Human Reproduction and Embryology heard Monday.

2 Jul 2010

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

2 Jul 2010

Columbia Laboratories shareholders approve Watson's aquisition terms

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that shareholders of Columbia Laboratories, Inc. (Nasdaq: CBRX) have approved the terms and conditions of the previously announced acquisition by Watson of the U.S. rights to Columbia's CRINONE® and PROCHIEVE® progesterone gel product line and 11,200,000 shares of Columbia common stock.

2 Jul 2010

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Chelsea Therapeutics International, Ltd. announced the completion and favorable outcome of an independent Data Monitoring Committee (DMC) review of the safety and efficacy data from approximately half the target enrollment in Chelsea's Phase II trial of droxidopa in fibromyalgia.

2 Jul 2010

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

Compugen Ltd. announced today that administration of CGEN-15001 in an animal model of multiple sclerosis (MS) has been shown to completely abolish spontaneous relapses. In addition, administration of this novel molecule prior to disease onset demonstrated a pronounced delay of disease onset and a significant decrease in disease symptoms.

2 Jul 2010

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Older patients with Hodgkin lymphoma (HL) and a history of heart disease face a high risk of hospitalization for cardiac complications after completing treatment, according to research published online today in Blood, the journal of the American Society of Hematology. HL is a form of cancer of arising in the lymph nodes, and approximately 8,500 people were diagnosed with the disease in 2009, according to the American Cancer Society.

2 Jul 2010

Elements Behavioral Health acquires The Ranch in Tennessee

Elements Behavioral Health, provider of residential treatment services for addiction and co-occurring disorders, announced this week the acquisition of The Ranch in Nunnelly, Tennessee. Elements is best known to the public as the owner of the internationally famous Promises Treatment Centers in Malibu and Los Angeles, where many Hollywood celebrities have been treated successfully for substance abuse.

2 Jul 2010

UCLA study highlights traffic-related asthma flares in urban areas

A new academic study led by UCLA scientists has found that even brief exposure to ultrafine pollution particles near a Los Angeles freeway is potent enough to boost the allergic inflammation that exacerbates asthma.

2 Jul 2010

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology.

2 Jul 2010

Cancer stem cells may vary from tumor to tumor, say researchers

Cancer stem cells have enticed scientists because of the potential to provide more durable and widespread cancer cures by identifying and targeting the tumor's most voracious cells.

2 Jul 2010

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

Scientists and engineers from around the globe will gather in August to share new information regarding neurorehabilitation advances for people with neurological movement disorders, including spinal cord and brain injures.

2 Jul 2010

Neuros Medical receives $1.5M Applied Research and Technology Development Award from DMRDP

Neuros Medical, Inc., a medical device company announced today they have received notification of award for $1.5 million from the U.S. Department of Defense. The Applied Research and Technology Development Award was provided by the Defense Medical Research and Development Program (DMRDP).

2 Jul 2010

Older men with high testosterone levels more likely to have heart attacks

A large U.S. multicenter study shows that older men with higher testosterone levels are more likely to have a heart attack or other cardiovascular disease in the future. The results were presented at The Endocrine Society's 92nd Annual Meeting in San Diego.

2 Jul 2010

Clinical study proves effectiveness of acupuncture for heart patients

Acupuncture can improve exercise tolerance in patients suffering from chronic heart failure. This was determined in a clinical pilot study by the team headed by Dr. Johannes Backs, physician and study director at the Department of Internal Medicine III (Cardiology, Angiology, and Pneumology - Medical Director: Professor Dr. Hugo Katus) of Heidelberg University Hospital.

2 Jul 2010

GSK, Genmab amend ofatumumab agreement

GlaxoSmithKline and Genmab A/S announced today an amendment to the ofatumumab co-development and commercialisation agreement. Under the terms of the amendment, GSK will take responsibility for developing ofatumumab in autoimmune indications whilst continuing to jointly develop ofatumumab with Genmab in oncology indications.

2 Jul 2010

Scientists explain mechanism behind acute myeloid leukemia

New research by scientists at Cold Spring Harbor Laboratory (CSHL) has illuminated in fine detail one of the genetic paths that leads to a particularly aggressive form of leukemia.

2 Jul 2010

Therapy News and Research

Eli Lilly, Alnara sign definitive merger agreement

Study: ONGLYZA and metformin improve HbA1c levels for adult patients with type 2 diabetes at 76-weeks

Modified Citrus Pectin holds promise against prostate cancer

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

EU requirement for HIV, hepatitis screening of ART couples at each donation unnecessary, distressing

Sensor-augmented insulin-pump therapy effective for type 1 diabetes patients

Columbia Laboratories shareholders approve Watson's aquisition terms

Chelsea reports positive outcome from DMC review of droxidopa Phase II trial in fibromyalgia

Compugen's CGEN-15001 recombinant fusion protein abolishes spontaneous relapses in animal model of MS

HL patients with heart disease at increased risk of hospitalization for cardiac complications after treatment

Elements Behavioral Health acquires The Ranch in Tennessee

UCLA study highlights traffic-related asthma flares in urban areas

Allogeneic stem cell transplant holds promise for treatment-resistant chronic lymphocytic leukemia

Cancer stem cells may vary from tumor to tumor, say researchers

Experts to discuss latest advancements in neurological disorders at Neurorehabilitation Symposium

Neuros Medical receives $1.5M Applied Research and Technology Development Award from DMRDP

Older men with high testosterone levels more likely to have heart attacks

Clinical study proves effectiveness of acupuncture for heart patients

GSK, Genmab amend ofatumumab agreement

Scientists explain mechanism behind acute myeloid leukemia

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News